4//SEC Filing
Fenton Mary Kay 4
Accession 0001193125-26-002687
CIK 0001789972other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 5:01 PM ET
Size
5.7 KB
Accession
0001193125-26-002687
Insider Transaction Report
Form 4
Fenton Mary Kay
Chief Financial Officer
Transactions
- Award
Common Stock
2025-12-31$6.49/sh+27$175→ 62,028 total
Footnotes (3)
- [F1]The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of July 1, 2025 through December 31, 2025. This transaction is also exempt under Rule 16b-3(c).
- [F2]In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on July 1, 2025.
- [F3]Includes 2,001 shares of common stock that the Reporting Person purchased pursuant to the Issuer's 2021 Employee Stock Purchase Plan for the purchase period of January 1, 2025 through June 30, 2025 that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Documents
Issuer
Cullinan Therapeutics, Inc.
CIK 0001789972
Entity typeother
Related Parties
1- filerCIK 0001378589
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 5:01 PM ET
- Size
- 5.7 KB